159992 创新药
已收盘 04-19 15:00:00
资讯
新帖
简况
中国生物制药(01177.HK)创新药罗伐昔替尼片关键注册研究达主要终点
阿斯达克财经 · 04-19 01:08
中国生物制药(01177.HK)创新药罗伐昔替尼片关键注册研究达主要终点
中国生物制药(01177.HK)三款创新药在AACR公布六项研究成果
阿斯达克财经 · 04-11
中国生物制药(01177.HK)三款创新药在AACR公布六项研究成果
【AH互动】上海医药(02607)涨超7% A股逆向下行 机构料创新药业务迎来收获期
金吾财讯 · 04-08
【AH互动】上海医药(02607)涨超7% A股逆向下行 机构料创新药业务迎来收获期
《大行报告》中金升翰森制药(03692.HK)目标价27.2%至17.81元 创新药收入占比提升
阿斯达克财经 · 03-28
《大行报告》中金升翰森制药(03692.HK)目标价27.2%至17.81元 创新药收入占比提升
【券商聚焦】招银国际微削信达生物(01801)目标价4% 仍为该行在创新药板块首选标的
金吾财讯 · 03-22
【券商聚焦】招银国际微削信达生物(01801)目标价4% 仍为该行在创新药板块首选标的
3月20日华夏广发博时永赢国联等基金大咖说:创新药是“新质生产力”吗?华夏现场直击英伟达2024GTC大会
新浪基金 · 03-19
3月20日华夏广发博时永赢国联等基金大咖说:创新药是“新质生产力”吗?华夏现场直击英伟达2024GTC大会
东诚药业旗下米度生物融资近4亿聚焦创新药
证券时报 · 03-19
东诚药业旗下米度生物融资近4亿聚焦创新药
商业健康险去年对创新药支付总额达74亿元
港股那点事 · 03-18
商业健康险去年对创新药支付总额达74亿元
美国BIO称将剔除药明康德会员资格 创新药板块迎来冲击?
券商中国 · 03-14
美国BIO称将剔除药明康德会员资格 创新药板块迎来冲击?
创新药板块集体拉升 多股涨超10% 机构:行业有望进入良性提质增速阶段
第一财经 · 03-14
创新药板块集体拉升 多股涨超10% 机构:行业有望进入良性提质增速阶段
网传文件被传重磅利好!港股创新药概念股集体走高
老虎资讯综合 · 03-14
网传文件被传重磅利好!港股创新药概念股集体走高
创新药行业迎来全链条政策支持,产业链正逐渐崛起
格隆汇 · 03-14
创新药行业迎来全链条政策支持,产业链正逐渐崛起
中国生物制药两款创新药将在AACR公布共5项研究结果
阿斯达克财经 · 03-12
中国生物制药两款创新药将在AACR公布共5项研究结果
3月7日华夏嘉实大成国投瑞银等基金大咖说:热辣滚烫的投资“基”会——可转债!聊聊创新药行业的几条主线
新浪基金 · 03-06
3月7日华夏嘉实大成国投瑞银等基金大咖说:热辣滚烫的投资“基”会——可转债!聊聊创新药行业的几条主线
全国人大代表、齐鲁制药集团总裁李燕:建议规范明确新上市创新药的范围和价格规则
每日经济新闻 · 03-05
全国人大代表、齐鲁制药集团总裁李燕:建议规范明确新上市创新药的范围和价格规则
众生药业公告,控股子公司一类创新药RAY
港股那点事 · 02-27
众生药业公告,控股子公司一类创新药RAY
众生药业:控股子公司一类创新药RAY12
港股那点事 · 02-21
众生药业:控股子公司一类创新药RAY12
创新药物马立巴韦片在中国投入临床使用
美通社 · 02-09
创新药物马立巴韦片在中国投入临床使用
加载更多
公司概况
公司名称:
--
所属市场:
上市日期:
--
主营业务:
发行价格:
--
{"stockData":{"symbol":"159992","market":"SZ","secType":"STK","nameCN":"创新药","latestPrice":0.655,"timestamp":1713510228000,"preClose":0.666,"halted":0,"volume":240056002,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.011,"latestTime":"04-19 15:00:00","open":0.662,"high":0.662,"low":0.65,"amount":157000000,"amplitude":0.018,"askPrice":0.655,"askSize":50029,"bidPrice":0.654,"bidSize":17640,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1713749400000},"adr":0,"adjPreClose":0.666,"symbolType":"fund","openAndCloseTimeList":[[1713490200000,1713497400000],[1713502800000,1713510000000]],"highLimit":0.733,"lowLimit":0.599,"ibTradeSell":false,"ibTradeBuySell":true,"pbRate":0,"committee":-0.192207,"marketValue":0,"floatMarketCap":0,"changeRate":-0.0165,"turnoverRate":0,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2024-04-22。","discountRate":"0.00%","netWorth":"0.000"},"requestUrl":"/m/hq/s/159992/","defaultTab":"news","newsList":[{"id":"2428251730","title":"中国生物制药(01177.HK)创新药罗伐昔替尼片关键注册研究达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2428251730","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2428251730?lang=zh_cn&edition=full","pubTime":"2024-04-19 01:08","pubTimestamp":1713460080,"startTime":"0","endTime":"0","summary":"中国生物制药(01177.HK) 公布,集团自主研发的1类创新药罗伐昔替尼片“Rovadicitinib(TQ05105)”用于治疗中高危骨髓纤维化的关键注册临床研究已达主要终点。集团将于近期递交TQ05105片的上市申请。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-18 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220728114526454_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220728114526454_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1343409/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2426445192","title":"中国生物制药(01177.HK)三款创新药在AACR公布六项研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2426445192","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2426445192?lang=zh_cn&edition=full","pubTime":"2024-04-11 01:53","pubTimestamp":1712771580,"startTime":"0","endTime":"0","summary":"中国生物制药(01177.HK) 公布,集团开发的三款创新药“盐酸安罗替尼胶囊”、“TQB2916(CD40激动剂)”、“FHND6091(蛋白酶体抑制剂)”已在2024年美国癌症协会年会(AACR)公布6项研究成果。研究表明,安罗替尼(消化道肿瘤)联合化疗一线治疗伴不可切除肝转移消化道肿瘤,尤其是胰腺癌,响应良好,有望为患者提供一种新的治疗策略。TQB2916能够与CD40结合,增加细胞因子释放,激活免疫,起到抗肿瘤作用。FHND6091的药理属性得到了全面验证。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-10 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1341413/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2425600021","title":"【AH互动】上海医药(02607)涨超7% A股逆向下行 机构料创新药业务迎来收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2425600021","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2425600021?lang=zh_cn&edition=full","pubTime":"2024-04-08 10:33","pubTimestamp":1712543618,"startTime":"0","endTime":"0","summary":"金吾财讯 | 上海医药 开盘后股价震荡走高,截至发稿,涨7.07%,报10.90港元,成交额1487万港元。A股方面,上海医药跌1.50%,报17.12元人民币。消息面上,华兴证券发布研报指,公司2023年实现年实现营收2630 亿元,同比增长12%;归母净利润37.68亿元,同比下降33%;扣非归母净利润35.96亿元,同比下降16%。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/ZDVjZjI4MzkxNjI4NTkwMDQ5NTQ5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZDVjZjI4MzkxNjI4NTkwMDQ5NTQ5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1934571","is_publish_highlight":false,"gpt_icon":0},{"id":"2422901984","title":"《大行报告》中金升翰森制药(03692.HK)目标价27.2%至17.81元 创新药收入占比提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2422901984","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2422901984?lang=zh_cn&edition=full","pubTime":"2024-03-28 10:08","pubTimestamp":1711591680,"startTime":"0","endTime":"0","summary":"中金发表报告指,翰森制药去年收入101亿元人民币,按年增长7.7%;净利润32.8亿元人民币,按年增长26.9%,高于该行预期,主因产品对外授权的首付款记账。该行指,关注翰森制药今年创新药进一步放量和早期临床管线数据读出。中金指,由于合作首付款记账部分将于今年确认,加上预期公司三费控制良好,因此上调今年收入和净利润预测各2%和11%至115.66和34.3亿人民币,首次引入明年盈利预测35.6亿元。维持“跑赢行业”评级,上调目标价27.2%至17.81港元。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20201021164017612_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20201021164017612_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1338136/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2421085590","title":"【券商聚焦】招银国际微削信达生物(01801)目标价4% 仍为该行在创新药板块首选标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2421085590","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2421085590?lang=zh_cn&edition=full","pubTime":"2024-03-22 14:10","pubTimestamp":1711087819,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际发研报指,信达生物 2023年录得总收入62.1亿元人民币,其中产品销售收入57.3亿元人民币,符合该行的预期。信达生物2H23表现强劲,产品销售额较上半年增长33.1%。信达生物还在探索IBI343与自有PD-1信迪利单抗和VEGFR-2雷莫芦单抗联合用于1L和2LGC的潜力。该行认为IBI343由于优秀的安全性和令人满意的疗效而具有全球BIC潜力。该行指,信达生物是该行在创新药板块的首选标的,该行调整公司目标价为55.00港元,维持买入评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1933865","is_publish_highlight":false,"gpt_icon":0},{"id":"2420216084","title":"3月20日华夏广发博时永赢国联等基金大咖说:创新药是“新质生产力”吗?华夏现场直击英伟达2024GTC大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2420216084","media":"新浪基金","top":-1,"share":"https://www.laohu8.com/m/news/2420216084?lang=zh_cn&edition=full","pubTime":"2024-03-19 15:49","pubTimestamp":1710834540,"startTime":"0","endTime":"0","summary":" 2024-03-20 10:00天弘基金:强势回归!新能源车能否顺风而上? 2024-03-20 10:30国联基金 杜伟、阳阳:创新药是“新质生产力”吗? 2024-03-20 13:30 天弘基金:全球AI风向标! 2024-03-20 15:00东财基金姚楠燕、王陈怡:交投情绪回暖,券商何时启航? 2024-03-20 15:30博时基金 刘玉强、洪露娉:专精特新“小巨人”! 2024-03-20 16:00广发基金 刘杰:成长风格强势回归,创业板投资怎么看?股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/money/fund/2024-03-19/doc-inanvyns9309001.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/2024-03-19/doc-inanvyns9309001.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2420237265","title":"东诚药业旗下米度生物融资近4亿聚焦创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2420237265","media":"证券时报","top":-1,"share":"https://www.laohu8.com/m/news/2420237265?lang=zh_cn&edition=full","pubTime":"2024-03-19 07:03","pubTimestamp":1710802980,"startTime":"0","endTime":"0","summary":" 3月18日,东诚药业公告,同意下属子公司米度(烟台)生物技术有限公司增资扩股,由国投招商领投,国投聚力、山东地方产业基金等跟投,合计融资近4亿元。 在非核药领域,米度生物作为分子影像CRO,在小分子、多肽、抗体、多糖、细胞治疗等创新品类上的临床前分子标记能力卓越,具有良好的放射性示踪剂生产和影像分析能力,并获得全球知名药企的认可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/s/2024-03-19/doc-inanvcia9687900.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2024-03-19/doc-inanvcia9687900.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2420465045","title":"商业健康险去年对创新药支付总额达74亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2420465045","media":"港股那点事","top":-1,"share":"https://www.laohu8.com/m/news/2420465045?lang=zh_cn&edition=full","pubTime":"2024-03-18 06:16","pubTimestamp":1710713760,"startTime":"0","endTime":"0","summary":"自2015年药品审评审批制度改革以来,我国创新药产业新药获批数量逐年增加,上市速度大大加快。日前,由波士顿咨询、中再寿险以及镁信健康共同编撰的《中国商业健康险创新药支付白皮书(2024)》(简称《白皮书》)正式发布。《白皮书》调查研究显示,2023年创新药市场规模约1400亿元,商业健康险对创新药的支付总额约74亿元,占整体市场规模的5.3%。 \n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-03-18/doc-inanstzy5857435.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-03-18/doc-inanstzy5857435.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2419611441","title":"美国BIO称将剔除药明康德会员资格 创新药板块迎来冲击?","url":"https://stock-news.laohu8.com/highlight/detail?id=2419611441","media":"券商中国","top":-1,"share":"https://www.laohu8.com/m/news/2419611441?lang=zh_cn&edition=full","pubTime":"2024-03-14 11:08","pubTimestamp":1710385680,"startTime":"0","endTime":"0","summary":" 创新药的崛起之路似乎并不平坦! 昨晚传出的一份《关于全链条支持创新药发展实施方案的征求意见稿》刺激了市场的神经。今天早盘,港股创新药ETF一度飙涨近10%。原因还是药明康德,这只股票亦是高开低走,大跌近5%。3月13日晚间,就在国内在为创新药利好欢呼之时,据美国知名生物技术组织BIO官网公布,宣布将剔除WuXi会员资格,并将终止与其合作。对于整个创新药板块是否也有冲击?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/jsy/2024-03-14/doc-inanhefw7961183.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/jsy/2024-03-14/doc-inanhefw7961183.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2419194076","title":"创新药板块集体拉升 多股涨超10% 机构:行业有望进入良性提质增速阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2419194076","media":"第一财经","top":-1,"share":"https://www.laohu8.com/m/news/2419194076?lang=zh_cn&edition=full","pubTime":"2024-03-14 10:02","pubTimestamp":1710381720,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 截至发稿,诺思格、泰格医药、昭衍新药、奥赛康、赛隆药业等多股涨停。 3月14日早盘,创新药板块大幅高开。 国开证券表示,今年以来,关于创新药顶层支持政策不断,同时创新药成功“出海”频出,行业有望进入良性提质增速阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-03-14/doc-inanfxxy8066621.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-03-14/doc-inanfxxy8066621.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"1182047658","title":"网传文件被传重磅利好!港股创新药概念股集体走高","url":"https://stock-news.laohu8.com/highlight/detail?id=1182047658","media":"老虎资讯综合","top":-1,"share":"https://www.laohu8.com/m/news/1182047658?lang=zh_cn&edition=full","pubTime":"2024-03-14 09:37","pubTimestamp":1710380248,"startTime":"0","endTime":"0","summary":"3月14日,港股创新药概念股集体走高,$泰格医药(03347)$涨超22%,$荣昌生物(09995)$涨超10%,消息面上,网传一份《全链条支持创新药发展实施方案(征求意见稿)》的文件,被市场解读为创新药行业的重磅利好。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"gpt_icon":0},{"id":"2419694951","title":"创新药行业迎来全链条政策支持,产业链正逐渐崛起","url":"https://stock-news.laohu8.com/highlight/detail?id=2419694951","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2419694951?lang=zh_cn&edition=full","pubTime":"2024-03-14 09:34","pubTimestamp":1710380049,"startTime":"0","endTime":"0","summary":"","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"gpt_icon":0},{"id":"2418933633","title":"中国生物制药两款创新药将在AACR公布共5项研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2418933633","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2418933633?lang=zh_cn&edition=full","pubTime":"2024-03-12 00:52","pubTimestamp":1710175920,"startTime":"0","endTime":"0","summary":"中国生物制药(01177.HK) 公布,附属正大天晴开发的两款创新药“盐酸安罗替尼胶囊”、“TQB2916(CD40激动剂)”将在2024年美国癌症协会年会“AACR”公布5项研究成果。安罗替尼是一款口服新型小分子多靶点受体酪氨酸激酶抑制剂(TKI),能有效抑制VEGFR 1-3等激酶,通过调控肿瘤微环境重编程达到抑制肿瘤血管新生、抑制肿瘤生长、调控免疫微环境的作用。CD40激动剂主要通过激活抗原提呈细胞(APC)促进免疫细胞的活化发挥肿瘤抑制作用。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-03-11 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190401142440846_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190401142440846_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1332490/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2417651232","title":"3月7日华夏嘉实大成国投瑞银等基金大咖说:热辣滚烫的投资“基”会——可转债!聊聊创新药行业的几条主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2417651232","media":"新浪基金","top":-1,"share":"https://www.laohu8.com/m/news/2417651232?lang=zh_cn&edition=full","pubTime":"2024-03-06 15:26","pubTimestamp":1709709960,"startTime":"0","endTime":"0","summary":" 2024-03-07 16:00合信岛春季集训营丨如何走进美丽人生下半场?从摸爬滚打到内心丰盈。 2024-03-07 19:30嘉实基金谭丽、晓鸥姐姐:播种2024,静待花开。股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/money/fund/2024-03-06/doc-inamkitk8808808.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/2024-03-06/doc-inamkitk8808808.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2417091591","title":"全国人大代表、齐鲁制药集团总裁李燕:建议规范明确新上市创新药的范围和价格规则","url":"https://stock-news.laohu8.com/highlight/detail?id=2417091591","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2417091591?lang=zh_cn&edition=full","pubTime":"2024-03-05 00:21","pubTimestamp":1709569260,"startTime":"0","endTime":"0","summary":"目前各地对于创新药挂网存在限价要求不统一、挂网路径不一致、创新药界定标准不统一等政策差异问题,建议医保部门规范明确新上市创新药的范围和价格规则,开通快速挂网通道,确保创新药上市后及时获得挂网准入资质。建议加强医疗机构对创新药合理配备使用的重视,必要时通过行政手段干预,要求医疗机构定期、系统地开展新药准入工作,保证创新药的市场准入。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-03-05/doc-inamesti1842281.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-03-05/doc-inamesti1842281.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2414824186","title":"众生药业公告,控股子公司一类创新药RAY","url":"https://stock-news.laohu8.com/highlight/detail?id=2414824186","media":"港股那点事","top":-1,"share":"https://www.laohu8.com/m/news/2414824186?lang=zh_cn&edition=full","pubTime":"2024-02-27 18:05","pubTimestamp":1709028300,"startTime":"0","endTime":"0","summary":"众生药业公告,控股子公司一类创新药RAY1225注射液用于2型糖尿病患者的II期临床试验完成首例受试者入组。 \n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-02-27/doc-inaknpfi3369332.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-02-27/doc-inaknpfi3369332.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2413449432","title":"众生药业:控股子公司一类创新药RAY12","url":"https://stock-news.laohu8.com/highlight/detail?id=2413449432","media":"港股那点事","top":-1,"share":"https://www.laohu8.com/m/news/2413449432?lang=zh_cn&edition=full","pubTime":"2024-02-21 19:09","pubTimestamp":1708513740,"startTime":"0","endTime":"0","summary":"众生药业:控股子公司一类创新药RAY1225注射液用于超重/肥胖患者的II期临床试验完成首例受试者入组。 \n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-02-21/doc-inaiuyrc0326270.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-02-21/doc-inaiuyrc0326270.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2410069567","title":"创新药物马立巴韦片在中国投入临床使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2410069567","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2410069567?lang=zh_cn&edition=full","pubTime":"2024-02-09 10:31","pubTimestamp":1707445860,"startTime":"0","endTime":"0","summary":"北京大学人民医院的黄晓军院士团队、南方医科大学的刘启发主任团队分别在北京和广州开出创新抗巨细胞病毒药物马立巴韦片的首张处方,标志着这一创新药物在中国投入临床使用,为我国难治性CMV感染或疾病的成人移植受者带来治疗新选择。同时,马立巴韦片与常规抗病毒治疗相比,治疗限制性毒性更低。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/usstock/c/2024-02-09/doc-inahmafs0343600.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-02-09/doc-inahmafs0343600.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"stockEarnings":[{"period":"1week","weight":-0.0253},{"period":"1month","weight":-0.1101},{"period":"3month","weight":-0.1161},{"period":"6month","weight":-0.1963},{"period":"1year","weight":-0.3047},{"period":"ytd","weight":-0.2061}],"compareEarnings":[{"period":"1week","weight":0.0152},{"period":"1month","weight":-0.0047},{"period":"3month","weight":0.0823},{"period":"6month","weight":0.0276},{"period":"1year","weight":-0.0896},{"period":"ytd","weight":0.0304}],"serverTime":1713572726425,"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"创新药,159992,创新药股票,创新药股票老虎,创新药股票老虎国际,创新药行情,创新药股票行情,创新药股价,创新药股市,创新药股票价格,创新药股票交易,创新药股票购买,创新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}